Loading data for VIRP.PA — first visit, this takes a few seconds.
Virbac SA (VIRP.PA)
Paris: VIRP.PA
· Real-Time Price · USD
332.00
+2.00 (0.61%)
At close: Sep 04, 2026, 3:35 PM
The price, the headline numbers and the latest news, in one place.
Virbac SA (VIRP.PA) Stock Price, Analysis & Data
No data available
| Bid | n/a |
| Market Cap | 2.67B |
| Revenue (ttm) | 1.46B |
| Net Income (ttm) | 151M |
| 0.77 | |
| 17.99 | |
| 17.73 | |
| 14.31 | |
| P/B (ttm) | 2.38 |
| P/S (ttm) | 1.83 |
| Earnings Date | Sep 17, 2026 |
| Ask | n/a |
| Volume | 1,414 |
| Avg. Volume (20D) | 4,168 |
| Open | 328.50 |
| Previous Close | 330.00 |
| Day's Range | 326.00 - 332.00 |
| 52-Week Range | 296.00 - 389.50 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $1.45 (0.45%) |
| Ex-Dividend Date | Jul 2, 2026 |
About VIRP.PA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, the United States, Brazil, and the Pacific. The company offers Vikaly, a cat food designed for the management of feline chronic kidney disease; Prevexto that contains imidacloprid and flumethrin, providing long-lasting parasite protection collar for dogs and cats at ri...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date Jul 7, 1992
Employees 6,442
Stock Exchange Paris
Ticker Symbol VIRP.PA
Website https://corporate.virbac.com
Financial Performance
In 2025, Virbac SA's revenue was 1.46B, an increase of 4.82% compared to the previous year's 1.4B. Earnings were 150.89M, an increase of 3.85%.
Financial numbers in EUR Financial StatementsEarnings Surprise
Virbac SA has released their quarterly earnings on Invalid Date:
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of misses estimates by , with NaN% YoY growth.
Virbac SA is scheduled to release its earnings on Sep 17, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2